

Full list of GSK's key presentations at ATS 2025

Abstract Name	Presenter	Presentation Details
Mepolizumab		
Mepolizumab Reduces the Risk of Severe Exacerbations and Healthcare Resource Utilization in Chronic Obstructive Pulmonary Disease: Results from the MATINEE Phase III Randomized Controlled Trial	Gerard J. Criner	Oral Presentation Abstract #10581 Session C14
Mepolizumab is Efficacious in Patients with Chronic Obstructive Pulmonary Disease Regardless of Airflow Obstruction Level: Post Hoc Analysis of the MATINEE Phase III Randomized Controlled Trial	MeiLan K. Han	Poster Discussion Abstract #8812 Poster Board #1017 Session B101
Mepolizumab is Efficacious in Patients with Chronic Obstructive Pulmonary Disease Regardless of Investigator-Reported Chronic Bronchitis and/or Emphysema: Post Hoc Analysis of the MATINEE Phase III Randomized Controlled Trial	Ian D. Pavord	Poster Discussion Abstract #8746 Poster Board #1012 Session B101
Mepolizumab is Efficacious in Patients With Chronic Obstructive Pulmonary Disease Regardless of Disease Duration: Post Hoc Analysis of the MATINEE Phase III Randomized Controlled Trial	Nicolas Roche	Late-breaker Poster Board #P669 Session C33
St. George's Respiratory Questionnaire Scores in Patients With Chronic Obstructive Pulmonary Disease Receiving Mepolizumab: Post Hoc Analysis of the MATINEE Phase III Randomized Controlled Trial	Paul W. Jones	Late-breaker Poster Board #P671 Session C33
Clinical Remission Is an Achievable Goal for Patients with Severe Asthma Receiving Mepolizumab in Europe: A Chart Review	Stephen G. Noorduyn	Thematic Poster Abstract #8721 Poster Board #P1461 Session A39
Mepolizumab Efficacy is Durable up to 104 Weeks in Patients with Chronic Obstructive Pulmonary Disease: Results from the MATINEE Phase III Randomized Controlled Trial	Mona Bafadhel	Thematic Poster Abstract #10722 Poster Board #P1380 Session A32
Mepolizumab is Efficacious Regardless of Severity of Prior Chronic Obstructive Pulmonary Disease Exacerbations: Post Hoc Analysis of the MATINEE Phase III Randomized Controlled Trial	Alberto Papi	Thematic Poster Abstract #10648 Poster Board #P1366 Session A32
Mepolizumab is Effective in Reducing Exacerbations in Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Comorbidities: Results from the MATINEE Phase III Randomized Controlled Trial	Claus F. Vogelmeier	Thematic Poster Abstract #10604 Poster Board #P1367 Session A32
Depemokimab		
Twice-Yearly Depemokimab Reduces Exacerbations and Improves Quality of Life in Patients with Uncontrolled Asthma Symptoms at Baseline: Subgroup Analyses of the Phase III SWIFT-1/2 Studies	Ian D. Pavord	Oral Presentation Abstract #10692 Session C14
Sustained Efficacy of Depemokimab Over Time in Type 2 Asthma Characterized by Blood Eosinophils: Pooled Data from the Phase III SWIFT-1/2 Studies	Michael E. Wechsler	Poster Discussion Abstract #6969 Poster Board #1007 Session B101
Real-World Persistence to Biologic Therapies and Its Impact on Outcomes in Patients with Asthma	Justin Kwiatek	Late-breaker Poster Board #724 Session C101

Regional Variation in Response to Depemokimab Versus Placebo in Patients with Asthma with Type 2 Inflammation: Subgroup Analyses of the Phase III SWIFT-1/2 Studies	David J. Jackson	Thematic Poster Abstract #12036 Poster Board #P1382 Session A32
Exploring Global Geographic Variation in Exacerbation Rates in Randomized Controlled Trials of Biologics in Patients with Severe Asthma: A Systematic Literature Review	David J. Jackson	Thematic Poster Abstract #6796 Poster Board #P1422 Session A34
Twice-Yearly Depemokimab Demonstrates Efficacy in Patients with Asthma in China and Japan: Subpopulation Analyses of the SWIFT-1/2 Studies	Toshiyuki Koya	Thematic Poster Abstract #11189 Poster Board #P1429 Session A34
Fluticasone Furoate/Umeclidinium/Vilanterol		
Effect of Chronic Mucus Hypersecretion on Patients with COPD Achieving and Maintaining Disease Stability with Fluticasone Furoate/Umeclidinium/Vilanterol Versus Budesonide/Formoterol: A FULFIL Post Hoc Analysis	Feng-yan Wang	Oral Presentation Abstract #10693 Session D14
Exacerbation Reduction in Patients with Asthma Following Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in the United States	Stephen G. Noorduyn	Oral Presentation Abstract #9347 Session C16
Assessment of Disease Stability in Patients with COPD Receiving Single-Inhaler Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI: Post Hoc Analysis of the IMPACT Trial	MeiLan K. Han	Oral Presentation Abstract #10784 Session A15
Impact of Fluticasone Furoate/Umeclidinium/Vilanterol Inhaled Therapy on a Clinical Remission Endpoint in Asthma for Patients with Type 2 Inflammation: CAPTAIN Post Hoc Analysis	Ian Pavord	Poster Discussion Abstract #8928 Poster Board #1010 Session B101
Impact of Simultaneous Step-Up to High-Dose Fluticasone Furoate and Addition of Umeclidinium on a Clinical Remission Endpoint in Asthma: CAPTAIN Post Hoc Analysis	Ian Pavord	Poster Discussion Abstract #9064 Poster Board #1011 Session B101
Comparison of Individual and Composite Measures to Assess Disease Stability Over Time in Patients with COPD Treated with Fluticasone Furoate/Umeclidinium/Vilanterol: A Post Hoc Analysis	MeiLan K. Han	Poster Discussion Abstract #10779 Poster Board #615 Session B25
Disease Stability, Management and Treatment Goals in Chronic Obstructive Pulmonary Disease Among Newly Diagnosed vs Long-Term Diagnosed Patients: A Patient Survey	David Halpin	Thematic Poster Abstract #10768 Poster Board #P262 Session B42
Salbutamol (albuterol)		
Decarbonizing Respiratory Care: The Impact of a Low-Carbon Salbutamol Metered-Dose Inhaler	Maximilian Plank	Late-breaker Poster Board #P657 Session C33
Camlipixant		
Investigating Camlipixant P2X3 Selectivity and Taste Disturbance: A Model-Based Dose-Response Meta-Analysis	Daren Austin	Thematic Poster Abstract #7825 Poster Board #P109 Session A54
Effect of Camlipixant on Cardiac Repolarization in Healthy Participants: A Thorough QT/QTc Study	Elizabeth A. Duncan	Thematic Poster Abstract #8877 Poster Board #P108

		Session A54
A Scoping Literature Review of Digital Endpoints for Chronic Cough Over the Past Five Years: Closing the Gap Between Clinical Trials and Real-World Clinical Practice	Elizabeth P. Skinner	Thematic Poster Abstract #7776 Poster Board #P256 Session B42